Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves

European Journal of Clinical Investigation

Volumn 41, Issue 11, 2011, Pages 1172-1179

  Côté, Nancy ^a   Couture, Christian ^b   Pibarot, Philippe ^b   Després, Jean Pierre ^b   Mathieu, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Angiotensin receptor blockers; Aortic stenosis; Remodelling; Weight

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; AORTIC VALVE WEIGHT; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLE REMODELING; HEART WEIGHT; HUMAN; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; PRIORITY JOURNAL; TRICUSPID VALVE; WAIST CIRCUMFERENCE;

AGE FACTORS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCIUM; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; RISK FACTORS; SEX FACTORS;

EID: 80053918228     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02522.x     Document Type: Article

References (39)

1. Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995;76:928-32.
2. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987;59:998-9.
3. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors - a causal relationship? A clinical morphologic study. Clin Cardiol 1991;14:995-9.
4. Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50years or older). Am J Cardiol 1985;55:744-7.
5. Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis 1984;37:407-15.
6. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
7. Zezulka A, Mackinnon J, Beevers DG. Hypertension in aortic valve disease and its response to valve replacement. Postgrad Med J 1992;68:180-5.
8. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32.
9. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-22.
10. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-53.
11. Olsson M, Rosenqvist M, Nilsson J. Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol 1994;24:1664-71.
12. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995;92:2163-8.
13. Mohler ER III, Adam LP, McClelland P, Graham L, Hathaway DR. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 1997;17:547-52.
14. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
15. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998;98:800-7.
16. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8.
17. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002;106:2224-30.
18. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-62.
19. Charest A, Pepin A, Shetty R, Cote C, Voisine P, Dagenais F et al. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 2006;92:1844-9.
20. Roberts WC, Ko JM. Relation of weights of operatively excised stenotic aortic valves to preoperative transvalvular peak systolic pressure gradients and to calculated aortic valve areas. J Am Coll Cardiol 2004;44:1847-55.
21. Roberts WC, Ko JM. Weights of operatively-excised stenotic unicuspid, bicuspid, and tricuspid aortic valves and their relation to age, sex, body mass index, and presence or absence of concomitant coronary artery bypass grafting. Am J Cardiol 2003;92:1057-65.
22. Warren BA, Yong JL. Calcification of the aortic valve: its progression and grading. Pathology 1997;29:360-8.
23. Mohty D, Pibarot P, Despres JP, Cote C, Arsenault B, Cartier A et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008;28:187-93.
24. Cote C, Pibarot P, Despres JP, Mohty D, Cartier A, Arsenault BJ et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94:1175-80.
25. Abdulla J, Sivertsen J, Kofoed KF, Alkadhi H, LaBounty T, Abildstrom SZ et al. Evaluation of aortic valve stenosis by cardiac multislice computed tomography compared with echocardiography: a systematic review and meta-analysis. J Heart Valve Dis 2009;18:634-43.
26. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009;53:577-84.
27. Cote N, Pibarot P, Pepin A, Fournier D, Audet A, Arsenault B et al. Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2010;145:444-9.
28. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006;47:2229-36.
29. Katz R, Budoff MJ, Takasu J, Shavelle DM, Bertoni A, Blumenthal RS et al. Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes 2009;58:813-9.
30. Mathieu P, Després JP, Pibarot P. The 'valvulo-metabolic' risk in calcific aortic valve disease. Can J Cardiol 2007;(Suppl. B):32B-9B.
31. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;9(Suppl.):229-34.
32. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61.
33. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
34. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
35. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306-14.
36. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007;49:1482-9.
37. O'Brien KD, Zhao XQ, Shavelle DM, Caulfield MT, Letterer RA, Kapadia SR et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med 2004;52:185-91.
38. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-5.
39. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-66.